Webster Equity Partners to buy Lifecore Biomedical in deal worth up to $660M
What's the deal? Lifecore BiomedicalDealroom has a profile for this one. Try Dealroom →, a Nasdaq-listed contract development and manufacturing organisation, has agreed to be acquired by private equity firm Webster Equity PartnersDealroom has a profile for this one. Try Dealroom → in a transaction valued at up to $663.7 million. Common stockholders will receive $6.28 per share in cash at closing, a 49.5% premium to Lifecore's September 25, 2026 closing price.
The terms: Beyond the cash payment, common and Series A preferred stockholders will receive contingent value rights (CVRs) worth up to $160 million if performance milestones are met. At full payout, holders could receive up to $9.67 per common equivalent — a premium of roughly 130.2%.
Why now? Lifecore says it is nearing an "inflection point," with several programs potentially commercialising by the end of 2028. Chief executive Paul Josephs said the company reviewed "a range of alternatives" before agreeing to the deal, which he said delivers "immediate and compelling value" to stockholders.
What's the endgame? Webster wants to pair its resources with Lifecore's CDMO capabilities. Partner Matthew Beer said the firm sees "an exciting opportunity for growth in the mid-term and beyond" as it pursues "sustainable profitability."
What changes: The acquisition takes Lifecore private. It is expected to close at the end of the fourth quarter of 2026, subject to stockholder approval and regulatory clearances.
The signal: The deal reflects continued private equity appetite for CDMOs, which handle drug development and manufacturing for pharmaceutical clients. The steep premium — and the milestone-linked CVRs — points to a buyer betting on a late-stage pipeline that has yet to reach commercial scale.
Read more: pr.lakeoconeebreeze.net
Image credit: Generated with Gemini
